☆ 4.4 Article

Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer

GEROSCIENCE (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Prognostic immunologic signatures in epithelial ovarian cancer

Nicole E. James et al.

Summary: EOC patients have low response rates to immunotherapies, but evidence suggests ovarian tumors are immunogenic and immune-related genomic profiles can serve as prognostic markers. Specific research areas that need to be addressed include developing immune-based prognostic signatures and driving advancements in this field.

ONCOGENE (2022)

Add to Collection

Article Oncology

AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer

Marko Hojnik et al.

Summary: This study evaluated the levels of AKR1B1 and AKR1B10 in patients with high-grade serous ovarian cancer and their association with clinicopathological characteristics, survival, and response to chemotherapy. The results showed that higher AKR1B1 levels were associated with better disease-free survival, making it a potential prognostic biomarker for this cancer. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy.

CANCERS (2022)

Add to Collection

Article Medicine, Research & Experimental

Discovery of new therapeutic targets in ovarian cancer through identifying significantly non-mutated genes

Halema Al-Farsi et al.

Summary: This study identifies significantly non-mutated genes in ovarian cancer patients, which are well-expressed in patient and cell line data, and demonstrates that silencing these genes can reduce viability in ovarian cancer cell lines.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Oncology

Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer

Rui Gou et al.

Summary: NUSAP1 is highly expressed in ovarian cancer, correlated with FIGO stage, and an independent risk factor affecting the prognosis of patients with epithelial ovarian cancer. It plays a role in cell cycle, DNA replication, homologous recombination, and p53 signaling pathway in ovarian cancer. Additionally, NUSAP1 expression is positively correlated with BRCA1/2, DNA mismatch repair genes, and immune cell infiltration in ovarian cancer.

BMC CANCER (2022)

Add to Collection

Review Oncology

Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease

Rebecca C. Arend et al.

Summary: Recent approved therapies have made significant progress in the treatment of ovarian cancer, but more options are needed to improve outcomes for patients with advanced disease. Novel combination strategies and agents targeting specific pathways are emerging as potential new treatment approaches for ovarian cancer, offering hope for improved treatment outcomes in the future.

CANCER BIOLOGY & THERAPY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues

Aron Bartha et al.

Summary: This study established an integrated database of gene expression data from tumor and metastatic tissues, identifying potential therapeutic targets for different cancer types. The online platform allows real-time mining and analysis of the database, providing valuable insights for cancer research and treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Multidisciplinary Sciences

Cyclin M2 (CNNM2) knockout mice show mild hypomagnesaemia and developmental defects

Gijs A. C. Franken et al.

Summary: Patients with mutations in Cyclin M2 (CNNM2) suffer from hypomagnesaemia, seizures, and intellectual disability. The study reveals the important role of CNNM2 in embryonic development and Mg2+ homeostasis, as well as a previously undescribed role in the intestine, which may contribute to Mg2+ deficiency in mice and patients.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences

Survival analysis in breast cancer using proteomic data from four independent datasets

Agnes Osz et al.

Summary: This study correlated immunohistochemical results with proteome-level technologies in identifying new prognostic biomarkers for breast cancer treatment selection. By integrating proteomic datasets and establishing a database for breast cancer patients, the study validated protein expression levels and identified candidate proteins as prognostic biomarkers. The large-scale proteomic studies provide sufficient data for validating and ranking potential protein biomarkers.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Potential Prognostic Immune Biomarkers of Overall Survival in Ovarian Cancer Through Comprehensive Bioinformatics Analysis: A Novel Artificial Intelligence Survival Prediction System

Tingshan He et al.

Summary: This study identified numerous differentially expressed genes and immune genes in ovarian cancer patients, constructed a survival prediction model using artificial intelligence algorithms, identified 14 prognostic immune biomarkers, and developed an AI survival predictive system that can provide individual mortality risk curves for ovarian cancer patients, aiding in personalized treatment decisions.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Review Oncology

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

Shuna Liu et al.

Summary: Ovarian cancer presents a serious threat to women's health due to its low early diagnosis rate and tendency for metastasis and recurrence. Conventional treatment involving platinum and paclitaxel chemotherapy based on surgery may not effectively address the recurrence and progression of the disease. By understanding the molecular pathways involved in ovarian cancer recurrence and progression, biomarker-guided treatment options have the potential to significantly improve patient prognosis and lead to personalized treatment strategies.

JOURNAL OF CANCER (2021)

Add to Collection

Article Cell Biology

Transmembrane adaptor protein WBP1L regulates CXCR4 signalling and murine haematopoiesis

Simon Borna et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)

Add to Collection

Review Oncology

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review

Lisa Belin et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Review Oncology

PARP inhibitors in ovarian cancer

Elisena Franzese et al.

CANCER TREATMENT REVIEWS (2019)

Add to Collection

Article Oncology

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial

Mary L. Disis et al.

JAMA ONCOLOGY (2019)

Add to Collection

Review Oncology

Ovarian Cancer: An Integrated Review

Christine Stewart et al.

SEMINARS IN ONCOLOGY NURSING (2019)

Add to Collection

Article Oncology

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients

Allison W. Kurian et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028

Andrea Varga et al.

GYNECOLOGIC ONCOLOGY (2019)

Add to Collection

Article Oncology

3-Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer

San-Duk Yang et al.

ONCOLOGY LETTERS (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin

Rong Yu et al.

CELL BIOCHEMISTRY AND FUNCTION (2018)

Add to Collection

Article Oncology

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis

Katrin M. Sjoquist et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Plk1 phosphorylation of CAP-H2 triggers chromosome condensation by condensin II at the early phase of mitosis

Yuya Kagami et al.

SCIENTIFIC REPORTS (2017)

Add to Collection

Article Biotechnology & Applied Microbiology

xCell: digitally portraying the tissue cellular heterogeneity landscape

Dvir Aran et al.

GENOME BIOLOGY (2017)

Add to Collection

Article Oncology

Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell Lines

Radoslaw Januchowski et al.

JOURNAL OF CANCER (2016)

Add to Collection

Article Obstetrics & Gynecology

Pathology of cancers of the female genital tract

Jaime Prat

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2015)

Add to Collection

Article Oncology

Loss of ASAP3 destabilizes cytoskeletal protein ACTG1 to suppress cancer cell migration

Yu Luo et al.

MOLECULAR MEDICINE REPORTS (2014)

Add to Collection

Article Biochemical Research Methods

Jetset: selecting the optimal microarray probe set to represent a gene

Qiyuan Li et al.

BMC BIOINFORMATICS (2011)

Add to Collection

Article Biochemistry & Molecular Biology

Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity

Tsukasa Baba et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.